Press-release for stocks for CLNN

Prices are updated after-hours

| -19.05% | O: -3.81% H: 5.64% C: -0.99%
au8 disease publication protein neurodegenerative

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -23.42% | O: 9.91% H: 0.0% C: -9.92%
year financial results

Clene to Present at the 36th Annual ROTH Conference
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -13.92% | O: 3.54% H: 2.44% C: -0.61%
conference

| -21.66% | O: 1.38% H: 3.0% C: -8.55%
au8 treatment extension trial results

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -24.39% | O: 2.33% H: 1.69% C: -6.56%
au8 als treatment

| 17.24% | O: 3.1% H: 23.58% C: 18.39%
au8 label treatment extension trial

| -33.98% | O: -34.37% H: 3.49% C: -6.8%
au8 label als biomarker treatment extension trial platform

Clene Provides Update on ALS Clinical Development Meeting With FDA
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -33.98% | O: -34.37% H: 3.49% C: -6.8%
fda als update meeting

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Published: 2023-12-14 (Crawled : 13:30) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -17.15% | O: 0.8% H: 10.73% C: 1.52%
cnm-au8 publication neurodegenerative

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -12.6% | O: 1.39% H: 13.84% C: 6.54%
financial results

| -31.19% | O: 4.43% H: 27.91% C: 5.31%
au8 drug health als awards research grant study

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Published: 2023-10-05 (Crawled : 14:30) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -31.19% | O: 4.43% H: 27.91% C: 5.31%
au8 health als awards grant study

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Published: 2023-09-28 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -35.61% | O: -1.52% H: 3.79% C: -3.85%
cnm-au8 publication

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -26.72% | O: 0.0% H: 31.44% C: 13.15%
conference global

| -26.57% | O: 4.51% H: 9.53% C: -4.11%
cnm-au8 als treatment trial platform

Clene to Present at Upcoming September Conferences
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -51.77% | O: 0.71% H: 8.45% C: 7.18%

| -51.2% | O: 6.22% H: 0.0% C: -4.73%
rescue-als year extension

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -52.51% | O: -3.0% H: 5.11% C: 4.42%
financial results

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
Published: 2023-08-02 (Crawled : 11:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K